Physician profile
Scott Melson
NPI 1518252360
$10,796.14
in general payments reported to CMS, 2019-2025
58 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,377 · 2020: $991 · 2021: $2,346 · 2022: $1,975 · 2023: $1,517 · 2024: $1,079 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,085.47 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,258.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,176.30 | 2019-2025 | Jardiance, Spiriva Respimat, Synjardy |
| Abbvie INC. | $1,154.55 | 2020-2025 | |
| Lilly USA, LLC | $1,093.52 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $973.05 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $723.00 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $510.60 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $295.26 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.33 | 2020-2025 | Xifaxan |
| Amgen INC. | $249.98 | 2019-2024 | Evenity, Prolia, Repatha |
| Corium, LLC | $216.50 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $192.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $176.82 | 2021-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $171.77 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $129.61 | 2024-2025 | Zenpep |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Melson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.